Research Article
Use of Remote Monitoring to Improve Outcomes in Patients with Heart Failure: A Pilot Trial
Table 1
Baseline characteristics and last one-year admissions.
| | Characteristics | Control | Intervention participants | Intervention non-participants | -value* |
| | Male gender (%) | 64.7 | 61.9 | 45 | .13 | | White race (%) | 90 | 83.5 | 87.5 | .64 | | Age, y, (mean ± SD) | 70.2 (±1.7) | 65.0 (±2.2) | 67.9 (±2.3) | .2 | | Depression (%) | 17.6 | 11.9 | 17.5 | .71 | | Hypertension (%) | 73.5 | 64.3 | 70 | .58 | | Diabetes (%) | 48.5 | 40.5 | 55 | .42 | | Creatinine mg/dl (mean ± SD) | 1.54 (±0.77) | 1.51 (±0.86) | 1.58 (±0.87) | .92 | | Ejection Fr. (mean ± SD) | 0.37 (±0.18) | 0.39 (±0.23) | 0.42 (±0.21) | .51 | | No. of Cardiac meds† | 6.2 (±0.24) | 6.1 (±0.31) | 5.7 (±0.32) | .41 | | Total no. of meds | 11.6 (±0.55) | 11.5 (±1.04) | 10.8 (±0.21) | .64 |
| | Readmissions per patient in last 12 months prior to index hospitalization (mean ± SD) |
| | All cause | 1.17 (±0.17) | 0.75 (±0.22) | 1.0 (±0.23) | .34 | | HF-related | 0.8 (±1.04) | 0.7 (±1.04) | 0.6 (±0.69) | .78 | | ER visits (mean ± SD) | | | | | | All cause | 1.34 (±1.47) | 1.26 (±1.99) | 1.65 (±1.83) | .16 | | HF-related | 0.5 (±0.76) | 0.57 (±1.34) | 0.9 (±0.90) | .007 |
|
|
. †Cardiac medications included Anticoagulants, vasodilators, digitalis, statins, diuretics, antiplatelet agents, angiotensin II receptor blockers, ACE-Inhibitors, Beta blockers, and calcium channel blocker.
|
